Marinomed Biotech has announced that its Solv4U unit is working with SPH Sine Pharmaceutical Laboratories to develop an OINDP formulation using Marinomed’s Marinosolv solubility enhancement technology. According to Marinomed, a feasibility study has been completed, and the companies expect to jointly seek a patent for the Marinosolv formulation. The announcement does not specify whether the product will be orally inhaled or nasal.
The Solv4U web site says that Marinosolv is a saponin-based technology that “enables a strongly increased solubilization and thereby enhanced bioavailability of hydrophobic small molecules and peptides.” Marinomed’s own pipeline includes Budesolve budesonide nasal spray, which is formulated with Marinosolv.
Marinomed CEO Andreas Grassauer commented, “We are proud to have successfully entered a first long-term partnership with our Solv4U business. The cooperation with SPH Sine is an incentive for us to put even more effort into the development and expansion of our Solv4U platform. It underlines once more the importance and potential of our Marinosolv technology. We hope that this agreement is just the beginning of many such partnerships, and we look forward to working closely with SPH Sine for the next few years.”
Solv4U Head Cornelia Sieg said, “Thanks to Solv4U, we can offer the outstanding properties of Marinosolv to pharma and biotech customers in the form of technology partnerships. Poor water solubility of drug candidates is an increasing challenge in pharmaceutical development. With Solv4U, we offer partners a clinically proven technology to develop more effective and sustainable drugs that ultimately benefit patients.”
Read the Marinomed Biotech press release.
